Cargando…

Case Report: Rapidly Progressive Interstitial Lung Disease in A Pregnant Patient With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

Dermatomyositis occurs extremely rarely during pregnancy. A number of studies in the published literature have documented how the outcome of pregnancy is poor for both mother and fetus. The present case study reports on a patient who was diagnosed with clinically amyopathic dermatomyositis complicat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Cuihong, Chen, Yulan, Huang, Qin, Hu, Qiu, Hong, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947909/ https://www.ncbi.nlm.nih.gov/pubmed/33717138 http://dx.doi.org/10.3389/fimmu.2021.625495

Ejemplares similares

Predictors of rapidly progressive interstitial lung disease and prognosis in Chinese patients with anti-melanoma differentiation-associated gene 5-positive dermatomyositis
por: Li, Meiqi, et al.
Publicado: (2023)

Prediction model for the pretreatment evaluation of mortality risk in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease
por: Gui, Xianhua, et al.
Publicado: (2022)

Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome
por: Zuo, Yu, et al.
Publicado: (2022)

Myocardial involvement is not rare in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis/clinically amyopathic dermatomyositis: a retrospective study
por: Zhou, Shuang, et al.
Publicado: (2022)

Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
por: Mehta, Asmita A, et al.
Publicado: (2021)

Slowly progressive interstitial lung disease preceding typical dermatomyositis symptoms in anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis
por: Isono, Taisuke, et al.
Publicado: (2021)

Clinical Features of Anti-MDA5 Antibody-positive Rapidly Progressive Interstitial Lung Disease without Signs of Dermatomyositis
por: Sakamoto, Noriho, et al.
Publicado: (2018)

Rare complications of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis: Time to nip them in the bud
por: Yang, Jinming, et al.
Publicado: (2022)

Clinical features and prognostic factors of anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis with rapidly progressive interstitial lung disease in Chinese patients
por: Lian, Li, et al.
Publicado: (2023)

Anti-PL-7 antibody-positive dermatomyositis with progressive interstitial pneumonia complicated with tracheal ulcer
por: Sato, Shintaro, et al.
Publicado: (2021)

Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis
por: Suzuki, Atsushi, et al.
Publicado: (2016)

2. Two cases of anti-MDA5 positive dermatomyositis with rapidly progressive interstitial lung disease
por: Levasseur, Kirsty, et al.
Publicado: (2019)

Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review
por: He, Chenjia, et al.
Publicado: (2022)

Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease
por: Li, Xiaomeng, et al.
Publicado: (2022)

Treatment of refractory anti-melanoma differentiation-associated gene 5 anbibody-positive dermatomyositis complicated by rapidly progressing interstitial pulmonary disease: Two case reports
por: Wang, Qiao-Hong, et al.
Publicado: (2023)

Acral Cutaneous Ulcerations and Livedo Reticularis with Rapidly Progressive Interstitial Lung Disease in Anti-MDA5 Antibody-Positive Classical Dermatomyositis
por: Wongjirattikarn, Rachot, et al.
Publicado: (2020)

Anti-MDA5 Antibody-positive Dermatomyositis with Rapidly Progressive Interstitial Pneumonia Presenting with Nephrotic Syndrome during Treatment with Corticosteroids and Cyclosporine
por: Kawamoto, Shinya, et al.
Publicado: (2021)

Mortality risk in patients with anti-MDA5 dermatomyositis is related to rapidly progressive interstitial lung disease and anti-Ro52 antibody
por: Wang, Huyan, et al.
Publicado: (2023)

Risk Prediction for Rapidly Progressive Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis: The CRAFT Model
por: Guo, Jinqiang, et al.
Publicado: (2023)

Successful treatment of plasma exchange for rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis: A case report
por: Endo, Yushiro, et al.
Publicado: (2018)

The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients
por: Chen, Xixia, et al.
Publicado: (2022)

Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients
por: Qian, Jinjing, et al.
Publicado: (2023)

Successful Treatment of Anti-MDA5 Antibody-Positive Dermatomyositis-Associated Rapidly Progressive-Interstitial Lung Disease by Plasma Exchange: Two Case Reports
por: Takahashi, Rina, et al.
Publicado: (2021)

Plasma exchange for anti-MDA5 antibody-positive dermatomyositis-associated rapidly progressive interstitial lung disease: A case report and literature review
por: Lu, Ci, et al.
Publicado: (2023)

Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease
por: Li, Liubing, et al.
Publicado: (2017)

Anti-MDA5 Associated Clinically Amyopathic Dermatomyositis With Rapidly Progressive Interstitial Lung Disease
por: Tavakolian, Kameron, et al.
Publicado: (2022)

Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis
por: Zhang, Suo, et al.
Publicado: (2022)

Double anti-PL-7 and anti-MDA-5 positive Amyopathic Dermatomyositis with rapidly progressive interstitial lung disease in a Hispanic patient
por: Li, Zi Ying, et al.
Publicado: (2020)

Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis
por: Li, Ting, et al.
Publicado: (2016)

A case of anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis‐associated rapidly progressive interstitial lung diseases developed after administration of COVID‐19 vaccine and subsequent pneumococcal vaccine
por: Takahashi, Saeko, et al.
Publicado: (2022)

Adrenomedullin Expression Is Associated With the Severity and Poor Prognosis of Interstitial Lung Disease in Dermatomyositis Patients
por: Ye, Lifang, et al.
Publicado: (2022)

Rapidly progressive melanoma differentiation–associated protein 5–positive amyopathic dermatomyositis in an HIV-positive patient
por: Sharma, Ashutosh, et al.
Publicado: (2017)

Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review
por: Yeung, Tsz-Wing, et al.
Publicado: (2021)

Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

Dermatomyositis With Anti-MDA5 Antibodies: Bioclinical Features, Pathogenesis and Emerging Therapies
por: Nombel, Anaïs, et al.
Publicado: (2021)

Fatal rapidly progressive interstitial lung disease in a patient with amyopathic dermatomyositis
por: Mobeireek, Abdullah, et al.
Publicado: (2021)

ECG Changes Through Immunosuppressive Therapy Indicate Cardiac Abnormality in Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis
por: Matsuo, Takashi, et al.
Publicado: (2022)

Clinically amyopathic dermatomyositis with interstitial lung disease double-positive for anti-MDA5 and anti-PL12 antibodies
por: Hiramatsu, Toshiya, et al.
Publicado: (2022)

Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review
por: Ogawa, Yuka, et al.
Publicado: (2017)

Correction: Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review
por: Nishi, Kentaro, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9o5obth2dqamd46bfmret0qjai